Beractant

Beractant is a pulmonary surfactant used in the treatment and prevention of neonatal respiratory distress syndrome (NRDS) in premature infants. This condition, also known as hyaline membrane disease, is a common complication in preterm newborns where the lungs are not fully developed, leading to difficulty in breathing. Beractant is a critical intervention that can significantly improve the survival rates and respiratory function of affected neonates.

Composition and Mechanism

Beractant is a synthetic surfactant that mimics the natural surfactant produced by the lungs. Natural lung surfactant reduces surface tension within the alveoli, preventing their collapse and facilitating gas exchange. Beractant contains phospholipids, neutral lipids, and surfactant-associated proteins that enhance its spreading and adsorption properties, thereby improving lung compliance and oxygenation in infants suffering from NRDS.

Indications

The primary indication for the use of beractant is the prevention and treatment of NRDS in premature infants. It is administered intratracheally shortly after birth to infants at risk of developing NRDS or as a rescue treatment to those already exhibiting symptoms of the disease.

Administration

Beractant is administered via intratracheal instillation, which requires intubation. The dosage and number of doses depend on the severity of the disease and the response to initial treatment. Careful monitoring of oxygenation, ventilation, and other vital parameters is essential during and after administration to adjust respiratory support as needed.

Efficacy and Safety

Clinical trials and studies have demonstrated the efficacy of beractant in reducing mortality and morbidity associated with NRDS. It has been shown to improve oxygenation and lung compliance, reduce the need for mechanical ventilation, and decrease the incidence of air leak syndromes. The safety profile of beractant is favorable, with infrequent and generally mild adverse effects. However, careful monitoring is necessary to manage potential complications related to the administration process, such as airway obstruction or bradycardia.

Conclusion

Beractant represents a significant advancement in the management of neonatal respiratory distress syndrome. Its development and use have led to improved outcomes for premature infants, reducing the burden of this condition on patients, families, and healthcare systems. Ongoing research and development in the field of neonatology continue to refine the use of beractant and explore new therapeutic strategies for respiratory diseases in neonates.